Study of BDTX-1535 for brain tumors with EGFR changes
Part of Cancer clinical trials.
This trial tests a new drug, BDTX-1535, for people with a type of brain tumor called high-grade glioma that has a specific change in the EGFR gene. The study looks at how the drug works in the body and how safe it is for both newly diagnosed and recurrent tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-grade glioma (WHO grade 3 or 4) that is either newly diagnosed or has come back after standard treatment.
- Your tumor has a confirmed change (alteration or fusion) in the EGFR gene.
- You are at least 18 years old.
- You need to have surgery to remove the tumor as part of this study.
- You must be in fairly good health overall, with adequate organ function and no uncontrolled infections or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called MT-125, combined with standard radiation and chemotherapy, is safe and effective for patients with a specific type of brain tumor (glioblastoma) that has a particular genetic feature (MGMT methylation). The goal is to see if this combination helps patients live longer without serious side effects.
This trial tests a new oral drug called XRD-0394 given together with radiation therapy for people with high-grade glioma, a type of aggressive brain tumor. The goal is to see if adding this drug makes radiation more effective.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial tests a new drug, MT027, for people with high-grade glioma (a type of brain tumor) that has come back or continued to grow after standard treatment. The drug targets a protein called B7-H3 found on tumor cells. The goal is to see if it can help shrink tumors or slow the disease.
This study is testing a new way to target radiation for people with high-grade gliomas (aggressive brain tumors). The goal is to see if a more precise treatment plan can improve outcomes while keeping side effects low.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.